Clinical trials: SARS
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Critical Illness, Pneumonia, Viral
D-Dimer as Predictor of Disease Outcome in Intensive Care Unit in COVID-19m Patients
Evaluating value of D-Dimer blood level of icu admitted patients on admission and 48 hours later as outcome predictor in SARS.COV.2 patients.
- Trial name
- COVID-19 (NCT05279469)
- Testing
- no intervention, just observational for D-Dimer level in blood
- Where
- 2 sites in Egypt
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Covid19, Telogen Effluvium
COVID-19 Induced Telogen Effluvium
This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection
- Conditions
- Covid19, Telogen Effluvium, SARS-CoV Infection, Alopecia
- Trial name
- NCT04834102
- Testing
- Blood Tests
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istanbul Medeniyet University
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection
Covid19
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)
- Trial name
- BIOMARK-COVID (NCT04664023)
- Testing
- Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection., Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
SARS-CoV-2 Infection, Covid19
Respiratory Aerosols in Patients With COVID-19 and Healthy Controls
The proposed study will investigate respiratory aerosols in SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus 2) positive and negative children and adults with the Resp-Aer-Meter (Palas GmbH).
- Trial name
- NCT04739020
- Testing
- Resp-Aer-Meter, Spirometry, Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations
- Where
- Germany
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
COVID-19
Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac-M for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of…
- Trial name
- NCT06068556
- Testing
- GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
SARS-CoV-2 Infection, Thalasemmie, SCD
Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes
There is an urgent need to rapidly evaluate anti-Covid 19 vaccination treatments, in terms of immune response (humoral and cell-mediated) together with the verification of the effectiveness of the vaccine in preventing SARS-CoV-2…
- Trial name
- HEMOGLOB-VAX (NCT05157256)
- Where
- 9 sites in Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Società Italiana Talassemie ed Emoglobinopatie
SARS-CoV 2
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and…
- Trial name
- SAPRIS-SERO (NCT04392388)
- Testing
- Non applicable
- Where
- France
- Volunteers
- 96,883 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
SARS-CoV-2, Covid19
Protecting Our Community: COVID-19 Testing
The COVID-19 pandemic has disproportionately affected American Indian (AI) and Latino communities, and these groups also have increased risk of poor prognosis due to high rates of chronic disease such as diabetes, cardiovascular…
- Trial name
- NCT04866303
- Testing
- Home-based SARS-CoV-2 test kit
- Where
- 2 sites in United States
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Montana State University
Covid19
Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first…
- Trial name
- COVID-19 (NCT04866069)
- Testing
- SARS-CoV-2 vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Osman ERGANIS, PhD, Prof
SARS-CoV-2, Anxiety and Fear
Covid-19 Anxiety and Phobia Levels of the Parents
A pandemic that originated in the Wuhan region of China in December 2019 was detected as a new type of coronavirus disease called coronavirus 2019 (COVID-19).
- Conditions
- SARS-CoV-2, Anxiety and Fear, Parents
- Trial name
- NCT04631172
- Testing
- Coronavirus Anxiety Scale , COVID-19 Phobia Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Selcuk University
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19, SARS-CoV Infection
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04530357
- Testing
- QazCovid-in® - COVID-19 inactivated vaccine
- Where
- Kazakhstan
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2
Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)
Study of the cellular immune response during the SARS-CoV-2 infection and identify cytokinic profiles in caregivers exposed to the virus with asymptomatic forms of COVID19, patients with an asymptomatic form followed in…
- Trial name
- CovImmune (NCT04355351)
- Testing
- blood sampling, additional blood tubes
- Where
- 3 sites in France
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
COVID-19 Vaccine, COVID-19
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.
- Trial name
- NCT05873374
- Testing
- 50 μg Baiya SARS-CoV-2 Vax 2
- Where
- Thailand
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
SARS-CoV2 Infection
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection.
- Trial name
- NCT05172024
- Where
- 86 sites in United States, Puerto Rico
- Volunteers
- 15,172 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.